Ivermectin reduces COVID-19 risk: real-time meta analysis of 106 studies (c19ivm ivmmeta)

Significantly lower risk is seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant for higher quality studies. 65 studies from 59 independent teams in 27 different countries show significant improvements.

Meta analysis using the most serious outcome shows 61% [50‑69%] and 84% [75‑89%] lower risk for early treatment and prophylaxis, with similar results for higher quality studies,

primary outcomes, peer-reviewed studies, and for RCTs.

Control Ivermectin

Results are very robust — in worst case exclusion sensitivity analysis 64 of 106 studies must be excluded to avoid finding statistically significant efficacy.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Pharmacokinetics show significant inter-individual variability1. Efficacy varies depending on the manufacturer2.

Over 20 countries adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of interest than typically used to approve drugs.

All data and sources to reproduce this analysis are in the appendix.

Multiple other meta analyses show efficacy3-7.

7 meta analyses show significant improvements with ivermectin for mortality1-6, hospitalization7, recovery3, and cases3.